Unibest 优贝德
← Back to patent-cliff list

CAS 1033962-64-9

3,5-Oxazolidinedicarboxylic acid, 2-(1-naphthalenyl)-4-phenyl-, 5-[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] 3-(1,1-dimethylethyl) ester, (2R,4S,5R)-

Codes(VI)140605-13-a

Application context (from source-drug indications)

膀胱癌多西他赛纳米胶束 (Samyang Biopharmaceuticals)头颈癌多西他赛纳米胶束 (Samyang Biopharmaceuticals)头颈部鳞状细胞癌多西他赛纳米胶束 (Samyang Biopharmaceuticals)实体瘤多西他赛纳米胶束 (Samyang Biopharmaceuticals)

Source drugs (routes using this intermediate)

DrugTierExpiry
多西他赛纳米胶束 (Samyang Biopharmaceuticals)Docetaxel polymeric micelle (Samyang Biopharmaceuticals)Tier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.